Immunofluorescent analysis of TSG101 showing staining in the cytoplasm of A549 cells. A549 cells were fixed in 2% paraformaldehyde at RT for 15 min, and be permeabilized in 0.1% saponin, 10% NGS, 100mM glycine for 30 min and stained using a TSG101 polyclonal antibody (Product # PA5-31260) diluted at 1:500. Blue: Hoechst 33342 staining.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant protein fragment corresponding to a region within amino acids 117 and 324 of Human TSG101|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7, with 20% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Western Blot (WB)||1:500-1:3000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-31260 targets TSG101 in ELISA, IF, and WB applications and shows reactivity with Human samples.
The PA5-31260 immunogen is recombinant protein fragment corresponding to a region within amino acids 117 and 324 of Human TSG101.
The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.